ArticlemAbs

Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors.

Susanne Wingert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.